Research design considerations for single-dose analgesic clinical trials in acute pain: IMMPACT recommendations

Stephen A Cooper1, Paul J Desjardins, Dennis C Turk

  • 1Stephen A. Cooper, LLC, Palm Beach Gardens, FL, USA Desjardins Associates, LLC and Department of Oral and Maxillofacial Surgery, Tufts University, Boston, MA, USA Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, WA, USA Departments of Anesthesiology, Neurology, and Biostatistics and Computational Biology, University of Rochester, Rochester, NY, USA Analgesic Solutions, Needham, MA, USA Section for Surgical Pathophysiology, Rigshospitalet, Copenhagen, Denmark Department of Health Services Research, University of Maryland, Baltimore, MD, LORA Group, LLC, Royal Oak, MD, USA Department of Orthopedic Surgery, Stanford University, Palo Alto, CA, USA American Chronic Pain Association, Rocklin, CA, USA Walter Reed Army Medical Center, Washington, DC, USA Departments of Pharmacology, Toxicology and Foundational Sciences, East Carolina University, Greenville, NC, USA Department of Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, USA Department of Anesthesiology, Queens University, Kingston, Ontario, Canada Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, WA, USA Eli Lilly & Co, Indianapolis, IN, USA Advise Clinical, Raleigh, NC, USA Department of Anaesthesia, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland United States Department of Veterans Affairs, New Haven, CT, USA Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University, Baltimore, MD, USA Analgesic Concepts, LLC, Arlington, VA, USA Johnson & Johnson Pharmaceutical Research and Development, Titusville, NY, USA Sorrento Therapeutics, San Diego, CA, USA Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden JohnsHopkinsUniversity, Baltimore, MD, USA, and Cara Therapeutics, Shelton, CN, USA Department of Emergency Medicine, MD Anderson Cancer Center, University of Texas, Houston, TX, USA NeurogesX, San Carlos, CA, USA Department of Anesthesiology, University of California San Diego, San Diego, CA, USA Pfizer, Inc, Groton, CT, USA Endo Pharmaceuticals, Chadds Ford, PA, USA.

Pain
|December 20, 2015
PubMed

Related Concept Videos

Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
335
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
2.9K
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
208
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
386
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
460
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs01:20

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...
368